Mark P. Schoenberg, M.D.

Mark P. Schoenberg, M.D.

Chief Medical OfficeratUroGen Pharma· In proxies 2022–2025

Pay in FY2025+33% from the year before · UroGen Pharma stock +119.9% the same year

Mark P. Schoenberg, M.D. was paid $1.2M in FY2025 (Dec), up 33%. UroGen Pharma stock rose 119.9% that year.

Pay$100 in the stock at the end of FY21 → $246
Pay is from the Summary Compensation Table of each UroGen Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. UroGen PharmaPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role +272%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?